# Gemcitabine + Docetaxel + Toripalimab Induction in Epstein-Barr Virus (EBV) Associated Nasopharyngeal Carcinoma(NPC)

> **NCT06592599** · PHASE2 · RECRUITING · sponsor: **Stanford University** · enrollment: 24 (estimated)

## Conditions studied

- Nasopharyngeal Carcinoma

## Interventions

- **DRUG:** Toripalimab
- **RADIATION:** Concurrent Chemoradiation and Adjuvant treatment following Chemoradiation

## Key facts

- **NCT ID:** NCT06592599
- **Lead sponsor:** Stanford University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-09-03
- **Primary completion:** 2029-01
- **Final completion:** 2029-01
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2026-02-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06592599

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06592599, "Gemcitabine + Docetaxel + Toripalimab Induction in Epstein-Barr Virus (EBV) Associated Nasopharyngeal Carcinoma(NPC)". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT06592599. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*